Characterization of KLHL14 anti-oncogenic action in malignant mesothelioma

Angelo Canciello1,2, Reyes Benot Domínguez1, Barbara Barboni2

  • 1Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA, 19122, USA.

Heliyon
|March 21, 2024
PubMed

Insights

Kelch-like 14 (KLHL14) protein prevents malignant mesothelioma progression by inhibiting epithelial-mesenchymal transition. Transforming Growth Factor β (TGF-β) regulates KLHL14, offering potential therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Malignant mesothelioma (MM) is an aggressive cancer with poor prognosis.
  • Limited therapeutic options necessitate identifying novel molecular targets.
  • Kelch-like (KLHL) proteins regulate cellular processes, but KLHL14 function is poorly understood.

Purpose of the Study:

  • To investigate the role of KLHL14 in malignant mesothelioma.
  • To elucidate the mechanism of action of KLHL14 in MM.
  • To explore the relationship between KLHL14 and Transforming Growth Factor β (TGF-β) signaling.

Main Methods:

  • Cell culture and manipulation of KLHL14 expression in MM cells.
  • Assessment of proliferation, motility, invasion, and colony formation.
  • Analysis of KLHL14 regulation by TGF-β, including synthesis, stability, and localization.

Main Results:

  • KLHL14 depletion enhanced MM cell proliferation, motility, invasion, and colony formation.
  • KLHL14 acts as an anti-oncogenic factor by preventing epithelial-mesenchymal transition (EMT).
  • TGF-β signaling positively regulates KLHL14 expression, stability, and nuclear-cytoplasmic shuttling.

Conclusions:

  • KLHL14 plays a critical anti-oncogenic role in malignant mesothelioma.
  • KLHL14's function is intrinsically linked to TGF-β signaling pathways.
  • Targeting KLHL14 or its interaction with TGF-β may offer novel therapeutic strategies for MM.